Jourdain G, et al. - Researchers aspired to determine the efficacy of tenofovir disoproxil fumarate (TDF) in the prevention of perinatal transmission of hepatitis B virus (HBV) compared to placebo. Data demonstrated that the additional maternal use of TDF did not lead to a markedly lower rate of transmission in a setting with a low rate of mother-to-child HBV transmission, with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to hepatitis B e antigen (HBeAg)-positive mothers.